# A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

> **NCT06090539** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 308 (estimated)

## Conditions studied

- Relapsed/Refractory Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** BMS-986458
- **DRUG:** Rituximab
- **DRUG:** Glofitamab/Obinutuzumab
- **DRUG:** Mosunetuzumab

## Key facts

- **NCT ID:** NCT06090539
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-29
- **Primary completion:** 2027-10-28
- **Final completion:** 2028-10-28
- **Target enrollment:** 308 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06090539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06090539, "A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT06090539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*